0.8593
price up icon1.25%   0.0106
pre-market  Vorhandelsmarkt:  .88   0.0207   +2.41%
loading
Schlusskurs vom Vortag:
$0.8487
Offen:
$0.85
24-Stunden-Volumen:
421.95K
Relative Volume:
0.45
Marktkapitalisierung:
$111.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-26.91M
KGV:
-3.9059
EPS:
-0.22
Netto-Cashflow:
$-19.57M
1W Leistung:
-6.07%
1M Leistung:
+8.77%
6M Leistung:
-10.24%
1J Leistung:
-41.94%
1-Tages-Spanne:
Value
$0.8401
$0.865
1-Wochen-Bereich:
Value
$0.8388
$0.93
52-Wochen-Spanne:
Value
$0.5526
$1.66

Atossa Therapeutics Inc Stock (ATOS) Company Profile

Name
Firmenname
Atossa Therapeutics Inc
Name
Telefon
206.588.0256
Name
Adresse
10202 5TH AVENUE NE, SEATTLE, WA
Name
Mitarbeiter
13
Name
Twitter
@atossainc
Name
Nächster Verdiensttermin
2025-03-25
Name
Neueste SEC-Einreichungen
Name
ATOS's Discussions on Twitter

Vergleichen Sie ATOS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ATOS
Atossa Therapeutics Inc
0.8593 118.16M 0 -26.91M -19.57M -0.22
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2018-01-26 Eingeleitet Maxim Group Buy

Atossa Therapeutics Inc Aktie (ATOS) Neueste Nachrichten

pulisher
Jul 22, 2025

Is Atossa Therapeutics Inc. a good long term investmentOutstanding capital returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Atossa Therapeutics Inc. stockTremendous wealth creation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Atossa Therapeutics Inc. stock priceFree Consultation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Why Atossa Therapeutics Inc. stock attracts strong analyst attentionHigh Potential Safe Trades - Newser

Jul 22, 2025
pulisher
Jul 20, 2025

Atossa Therapeutics Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 18, 2025

Should I buy Atossa Therapeutics Inc. stock before earningsHigh Win Rate Stock Ideas - Newser

Jul 18, 2025
pulisher
Jul 15, 2025

How Atossa Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Atossa Therapeutics Inc. stock price move sharplyTrade With Low Risk Exposure - Newser

Jul 15, 2025
pulisher
Jul 07, 2025

Ascendiant Lifts Atossa Therapeutics, Inc. (ATOS) Target Citing Strong Liquidity - MSN

Jul 07, 2025
pulisher
Jun 26, 2025

15 Best Growth Stocks to Invest in for the Next 5 Years - Insider Monkey

Jun 26, 2025
pulisher
Jun 15, 2025

Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World

Jun 15, 2025
pulisher
Jun 09, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Ascendiant Capital Markets Issues Positive Forecast for Atossa Therapeutics (NASDAQ:ATOS) Stock Price - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Craig Hallum Upgrades Atossa Therapeutics (NASDAQ:ATOS) to “Strong-Buy” - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Atossa Therapeutics (ATOS): Ascendiant Capital Raises Price Targ - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital raises Atossa Genetics stock price target to $7.50 By Investing.com - Investing.com India

Jun 06, 2025
pulisher
Jun 06, 2025

Ascendiant Capital raises Atossa Genetics stock price target to $7.50 - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Craig-Hallum Initiates Coverage of Atossa Therapeutics (BMV:ATOS) with Buy Recommendation - Nasdaq

Jun 06, 2025
pulisher
Jun 05, 2025

Craig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy Recommendation - Nasdaq

Jun 05, 2025
pulisher
Jun 05, 2025

This Excelerate Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Jun 05, 2025
pulisher
Jun 05, 2025

Craig-Hallum Initiates Coverage on Atossa Therapeutics (ATOS) with Buy Rating | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics at Jefferies Conference: Strategic Moves in Breast Cancer - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Craig-Hallum initiates Atossa Genetics stock with buy rating By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Ca - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Buy Rating with Promising Cancer Drug Potential | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Craig Hallum Initiates Coverage on Atossa Therapeutics With Buy Rating, $4 Price Target - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Atossa Therapeutics (ATOS) Receives Positive Coverage and Price Target | ATOS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference - Bluefield Daily Telegraph

Jun 02, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference | ATOS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Atossa Therapeutics CEO Reveals Latest Breast Cancer Drug Progress at Major Healthcare Conference - Stock Titan

Jun 02, 2025
pulisher
May 30, 2025

Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Northern Trust Corp - Defense World

May 30, 2025
pulisher
May 28, 2025

Atossa Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 28, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Atossa Therapeutics CEO Steven Quay buys $9,886 in common stock By Investing.com - Investing.com Nigeria

May 22, 2025

Finanzdaten der Atossa Therapeutics Inc-Aktie (ATOS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):